An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ocular Therapeutix (NASDAQ: OCUL) announced it will report its first quarter financial results for the period ending March 31, 2022, on May 9, 2022. Following the earnings release, the management team will host a conference call at 4:30 PM ET to discuss the financial results and provide a business update. Investors can access the live webcast via the company’s investor section of its website. Ocular Therapeutix focuses on developing innovative therapies for eye diseases, including its FDA-approved product DEXTENZA®.
Positive
Scheduled earnings report on May 9, 2022, signals ongoing financial transparency.
Focus on developing innovative therapies enhances growth potential.
Negative
None.
BEDFORD, Mass.--(BUSINESS WIRE)--
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2022 financial results on Monday, May 9, 2022. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update.
The live webcast can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (844) 464-3934 (U.S.) or (765) 507-2620 (International) to listen to the live conference call. The conference ID number for the live call will be 6054473. A replay of the webcast will be available on the Company’s website for 90 days following the live call.
About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets includes OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and other retinal diseases. OTX-TIC (travoprost intracameral implant) recently began a Phase 2 clinical trial to evaluate the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix has also completed Phase 2 clinical trials for OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix's first product, ReSure® Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.
Investors
Ocular Therapeutix Donald Notman Chief Financial Officer
dnotman@ocutx.com
or
Westwicke, an ICR Company Chris Brinzey, 339-970-2843
Managing Director
chris.brinzey@westwicke.com
Media
Ocular Therapeutix Scott Corning Senior Vice President, Commercial
scorning@ocutx.com
Source: Ocular Therapeutix, Inc.
FAQ
When will Ocular Therapeutix report its Q1 2022 financial results?
Ocular Therapeutix will report its Q1 2022 financial results on May 9, 2022.
What time is the Ocular Therapeutix earnings conference call?
The earnings conference call is scheduled for 4:30 PM ET on May 9, 2022.
Where can I access the Ocular Therapeutix earnings webcast?
The earnings webcast can be accessed via the Investors section of Ocular Therapeutix's website.
What is the primary focus of Ocular Therapeutix?
Ocular Therapeutix focuses on developing innovative therapies for diseases and conditions of the eye.
